RIGL - Rigel Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue20,38328,8958,250
Cost of Revenue--9,302
Gross Profit20,38328,895-1,052
Operating Expenses
Research Development63,44662,82567,696
Selling General and Administrative20,90817,81322,501
Non Recurring5,7705,7705,770
Total Operating Expenses---
Operating Income or Loss-69,741-51,743-91,249
Income from Continuing Operations
Total Other Income/Expenses Net525279341
Earnings Before Interest and Taxes-69,216-51,464-90,908
Interest Expense---
Income Before Tax-69,216-51,464-90,908
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-69,216-51,464-90,908
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-69,216-51,464-90,908
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-69,216-51,464-90,908